In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and their own experience, cardiologist Jorge Plutzy, MD, and endocrinologist Helena Rodbard, MD, navigate through a series of ‘clinical questions’ to inform regarding the clinical pharmacology of the GLP-1RAs and their evidence-based role in cardiovascular risk reduction, particularly in patients with secondary atherosclerotic cardiovascular disease.
Annenberg Center for Health Sciences
Sign up to track rankings and reviews from Spotify, Apple Podcasts and more.